Clinical impact of PET imaging in prostate cancer management
PURPOSE OF REVIEW: Imaging of prostate cancer has been a rapidly evolving field in recent years with the introduction of multiple new PET tracer agents. Introduction of novel imaging techniques into clinical practice requires careful evaluation, with the ultimate aims of improved patient outcomes, better sequencing of treatments, and cost effectiveness. The increased sensitivity and specificity of these new PET agents present both challenges and opportunities. We know they frequently change management, but are these effective management changes, and is it always in the best interests of the patients?.
RECENT FINDINGS: This review will focus on recent publications that provide high-level evidence for the use of PET in prostate cancer. It will discuss studies that have evaluated the clinical impact of PET imaging in prostate cancer and will review a number of trials that demonstrate the potential of PET to change current standard of care, from diagnosis, to prognostic capabilities in men with metastatic prostate cancer.
SUMMARY: Evidence for the use of PET in prostate cancer is building with studies evaluating diagnostic accuracy of PET at all stages of prostate cancer. We review the evidence available, focusing on prospective trials that are measuring the impact of new technology on patient outcomes.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:30 |
---|---|
Enthalten in: |
Current opinion in urology - 30(2020), 5 vom: 01. Sept., Seite 649-653 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Emmett, Louise [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antigens, Surface |
---|
Anmerkungen: |
Date Completed 17.12.2020 Date Revised 06.02.2021 published: Print Citation Status MEDLINE |
---|
doi: |
10.1097/MOU.0000000000000795 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM313081573 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM313081573 | ||
003 | DE-627 | ||
005 | 20231225145813.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1097/MOU.0000000000000795 |2 doi | |
028 | 5 | 2 | |a pubmed24n1043.xml |
035 | |a (DE-627)NLM313081573 | ||
035 | |a (NLM)32732622 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Emmett, Louise |e verfasserin |4 aut | |
245 | 1 | 0 | |a Clinical impact of PET imaging in prostate cancer management |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 17.12.2020 | ||
500 | |a Date Revised 06.02.2021 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a PURPOSE OF REVIEW: Imaging of prostate cancer has been a rapidly evolving field in recent years with the introduction of multiple new PET tracer agents. Introduction of novel imaging techniques into clinical practice requires careful evaluation, with the ultimate aims of improved patient outcomes, better sequencing of treatments, and cost effectiveness. The increased sensitivity and specificity of these new PET agents present both challenges and opportunities. We know they frequently change management, but are these effective management changes, and is it always in the best interests of the patients? | ||
520 | |a RECENT FINDINGS: This review will focus on recent publications that provide high-level evidence for the use of PET in prostate cancer. It will discuss studies that have evaluated the clinical impact of PET imaging in prostate cancer and will review a number of trials that demonstrate the potential of PET to change current standard of care, from diagnosis, to prognostic capabilities in men with metastatic prostate cancer | ||
520 | |a SUMMARY: Evidence for the use of PET in prostate cancer is building with studies evaluating diagnostic accuracy of PET at all stages of prostate cancer. We review the evidence available, focusing on prospective trials that are measuring the impact of new technology on patient outcomes | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 7 | |a Antigens, Surface |2 NLM | |
650 | 7 | |a FOLH1 protein, human |2 NLM | |
650 | 7 | |a EC 3.4.17.21 |2 NLM | |
650 | 7 | |a Glutamate Carboxypeptidase II |2 NLM | |
650 | 7 | |a EC 3.4.17.21 |2 NLM | |
700 | 1 | |a Hruby, George |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Current opinion in urology |d 1997 |g 30(2020), 5 vom: 01. Sept., Seite 649-653 |w (DE-627)NLM091554853 |x 1473-6586 |7 nnns |
773 | 1 | 8 | |g volume:30 |g year:2020 |g number:5 |g day:01 |g month:09 |g pages:649-653 |
856 | 4 | 0 | |u http://dx.doi.org/10.1097/MOU.0000000000000795 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 30 |j 2020 |e 5 |b 01 |c 09 |h 649-653 |